AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9758296 — intervention group
Group type: COMPARATOR
Intervention: No reinsertion of the stylet before needle removal
Number of subjects: 600
Study 7922005 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated enumeration method for CD34+ cells using a two-tube assay and dedicated software.
Number of subjects: 0
Study 7922005 — intervention group
Group type: COMPARATOR
Intervention: Control reagent combination using IgG1 control antibody labeled with PE.
Number of subjects: 0
Study 2974252 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose human [Ser-Tyr28]ANH infusion (1.1 pmol.kg-1.min-1)
Number of subjects: 8
Study 2974252 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 8
Study 2974252 — intervention group
Group type: COMPARATOR
Intervention: High-salt diet (HS)
Number of subjects: 8
Study 5071698 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylobarbitone
Number of subjects: 0
Study 5071698 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 0
Study 5071698 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent review by the doctor after the first prescription and cautionary advice to the patient
Number of subjects: 0
Study 31292734 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS with cognitive training (CT)
Number of subjects: 30
Study 31292734 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS with cognitive training (CT)
Number of subjects: 30
Study 28537898 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (500 mg twice daily)
Number of subjects: 340
Study 28537898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 25475435 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (0.6 g/kg fat-free mass; n = 11)
Number of subjects: 22
Study 25475435 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine (matched amount to whey protein; n = 11)
Number of subjects: 22
Study 25475435 — intervention group
Group type: COMPARATOR
Intervention: Control (no amino acid ingestion)
Number of subjects: 22
Study 23584840 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually adapted exercises and examination‐based physiotherapy
Number of subjects: 90
Study 23584840 — intervention group
Group type: COMPARATOR
Intervention: Individually adapted exercises only (Control)
Number of subjects: 90
Study 21531236 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide
Number of subjects: 154
Study 18751703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet use during operation
Number of subjects: 80
Study 18751703 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet use during operation
Number of subjects: 80
Study 16776703 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) in migraineurs with aura (MA)
Number of subjects: 25
Study 16776703 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) in migraineurs without aura (MoA)
Number of subjects: 25
Study 16776703 — intervention group
Group type: COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS) in control subjects
Number of subjects: 25
Study 16776703 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PT variability between migraineurs and controls
Number of subjects: 25
Study 16776703 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphene thresholds (PTs) in migraineurs
Number of subjects: 25
Study 14531592 — intervention group
Group type: EXPERIMENTAL
Intervention: StarBrite (35% hydrogen peroxide)
Number of subjects: 0
Study 14531592 — intervention group
Group type: COMPARATOR
Intervention: Opalescence Xtra Boost (38% hydrogen peroxide)
Number of subjects: 0
Study 10750206 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary patient-held record
Number of subjects: 650
Study 10750206 — intervention group
Group type: COMPARATOR
Intervention: Normal care (Control)
Number of subjects: 650
Study 9082588 — intervention group
Group type: EXPERIMENTAL
Intervention: MT+tactivin (T)
Number of subjects: 127
Study 9082588 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MT)
Number of subjects: 127
Study 1422715 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioptycut 14-G (B14)
Number of subjects: 151
Study 1422715 — intervention group
Group type: COMPARATOR
Intervention: Tru-Cut 14-G (T14)
Number of subjects: 151
Study 1422715 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioptycut 18-G (B18)
Number of subjects: 151
Study 6094194 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptin (2.5 mg, twice daily for 4 days)
Number of subjects: 30
Study 6094194 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 30
Study 31514988 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen mixture (65% nitrous oxide/oxygen)
Number of subjects: 60
Study 31514988 — intervention group
Group type: COMPARATOR
Intervention: Oxygen (control group)
Number of subjects: 60
Study 30213173 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative parecoxib administration (40 mg before skin incision and at 12 and 24 hours after the first dose)
Number of subjects: 127
Study 30213173 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative parecoxib administration (40 mg at wound closure and at 12 and 24 hours after the first dose)
Number of subjects: 127
Study 30213173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no parecoxib administration)
Number of subjects: 127
Study 27250001 — intervention group
Group type: EXPERIMENTAL
Intervention: CEFci arm (5‐Fu 200 mg/m(2) daily by 24‐h continuous infusion and epirubicin 100 mg/m(2) and cyclophosphamide 600 mg/m(2) intravenous bolus on day 1)
Number of subjects: 501
Study 27250001 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF arm (cyclophosphamide 600 mg/m(2), epirubicin 100 mg/m(2), and 5‐Fu 600 mg/m(2) i.v. on day 1)
Number of subjects: 501
Study 27250001 — intervention group
Group type: EXPERIMENTAL
Intervention: EC arm (epirubicin 100 mg/m(2) and cyclophosphamide 600 mg/m(2) i.v. on day 1)
Number of subjects: 501
Study 27250001 — intervention group
Group type: EXPERIMENTAL
Intervention: CEFci arm
Number of subjects: 501
Study 27250001 — intervention group
Group type: COMPARATOR
Intervention: CEF arm
Number of subjects: 501
Study 27250001 — intervention group
Group type: COMPARATOR
Intervention: EC arm
Number of subjects: 501
Study 27250001 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 501
Study 24329966 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of existing gas stove with electric stove
Number of subjects: 0
Study 24329966 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of air purifiers with HEPA and carbon filters
Number of subjects: 0
Study 24329966 — intervention group
Group type: COMPARATOR
Intervention: Installation of ventilation hood over existing gas stove
Number of subjects: 0
Study 21777294 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% water restriction
Number of subjects: 90
Study 21777294 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% water restriction
Number of subjects: 90
Study 21777294 — intervention group
Group type: COMPARATOR
Intervention: 0% water restriction (control)
Number of subjects: 90
Study 21777294 — intervention group
Group type: EXPERIMENTAL
Intervention: Water restriction (general)
Number of subjects: 90
Study 21777294 — intervention group
Group type: EXPERIMENTAL
Intervention: Water restriction (local group)
Number of subjects: 90
Study 21777294 — intervention group
Group type: EXPERIMENTAL
Intervention: Water restriction (commercial group)
Number of subjects: 90
Study 20925999 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal femoral nail antirotation device (PFNA)
Number of subjects: 106
Study 20925999 — intervention group
Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 106
Study 18588849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic morcellation
Number of subjects: 60
Study 18588849 — intervention group
Group type: COMPARATOR
Intervention: Conventional resectoscopy
Number of subjects: 60
Study 11441423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecopipam 10 mg p.o.
Number of subjects: 10
Study 11441423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecopipam 25 mg p.o.
Number of subjects: 10
Study 11441423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecopipam 100 mg p.o.
Number of subjects: 10
Study 11441423 — intervention group
Group type: COMPARATOR
Intervention: Cocaine 25 mg/70 kg i.v.
Number of subjects: 10
Study 11441423 — intervention group
Group type: COMPARATOR
Intervention: Cocaine 50 mg/70 kg i.v.
Number of subjects: 10
Study 11441423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecopipam (all doses)
Number of subjects: 10
Study 9644282 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 years DCD (6DCD)
Number of subjects: 40
Study 9644282 — intervention group
Group type: EXPERIMENTAL
Intervention: DCD (across both age groups)
Number of subjects: 40
Study 9644282 — intervention group
Group type: COMPARATOR
Intervention: Normal Coordination (NC) (across both age groups)
Number of subjects: 40
Study 7523724 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy combined with androgen deprivation
Number of subjects: 0
Study 7523724 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal 3-dimensional radiation therapy
Number of subjects: 0
Study 3372718 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (15 mg daily for 6 weeks)
Number of subjects: 0
Study 31145366 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus fire needle therapy
Number of subjects: 38
Study 31145366 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture alone
Number of subjects: 38
Study 29072164 — intervention group
Group type: EXPERIMENTAL
Intervention: SMOFlipid® (15% fish oil)
Number of subjects: 90
Study 29072164 — intervention group
Group type: COMPARATOR
Intervention: Clinoleic®
Number of subjects: 90
Study 25016389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided haematoma block (lidocaine 10%)
Number of subjects: 143
Study 25016389 — intervention group
Group type: COMPARATOR
Intervention: Procedural sedation and analgesia (intravenous midazolam plus fentanyl)
Number of subjects: 143
Study 25016389 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 143
Study 22681255 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural area dogs
Number of subjects: 197
Study 22681255 — intervention group
Group type: COMPARATOR
Intervention: Urban area dogs
Number of subjects: 197
Study 22681255 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunting dogs
Number of subjects: 197
Study 22681255 — intervention group
Group type: COMPARATOR
Intervention: Companion and kennel dogs
Number of subjects: 197
Study 22681255 — intervention group
Group type: COMPARATOR
Intervention: Age, gender, or breed
Number of subjects: 197
Study 22681255 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunting lifestyle
Number of subjects: 197
Study 21943082 — intervention group
Group type: EXPERIMENTAL
Intervention: Food appeal ratings
Number of subjects: 129
Study 21943082 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire to eat ratings
Number of subjects: 129
Study 21943082 — intervention group
Group type: COMPARATOR
Intervention: Desire to eat
Number of subjects: 129
Study 21943082 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy density of foods
Number of subjects: 129
Study 19092112 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 52
Study 19092112 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine CR
Number of subjects: 52
Study 19092112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 19092112 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline vs Paroxetine CR
Number of subjects: 52
Study 16816394 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil in ropivacaine (Group S, n=30)
Number of subjects: 60
Study 16816394 — intervention group
Group type: COMPARATOR
Intervention: Morphine in ropivacaine (Group M, n=30)
Number of subjects: 60
Study 14521657 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term variability in induced arrhythmias (group A)
Number of subjects: 40
Study 14521657 — intervention group
Group type: COMPARATOR
Intervention: No long-term variability in induced arrhythmias (group B)
Number of subjects: 40
Study 14521657 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A patients (long-term variability)
Number of subjects: 40
Study 14521657 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term variability
Number of subjects: 40
Study 14521657 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone therapy
Number of subjects: 40
Study 14521657 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction <35%
Number of subjects: 40
Study 10845748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation intervention (nicotine gum users)
Number of subjects: 3523
Study 10845748 — intervention group
Group type: COMPARATOR
Intervention: No nicotine gum after 1 year
Number of subjects: 3523
Study 10845748 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous quit attempts
Number of subjects: 3523
Study 10845748 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional coping association
Number of subjects: 3523
Study 9356762 — intervention group
Group type: EXPERIMENTAL
Intervention: Crank arm length of 165 mm
Number of subjects: 6
Study 9356762 — intervention group
Group type: EXPERIMENTAL
Intervention: Crank arm length of 170 mm
Number of subjects: 6
Study 9356762 — intervention group
Group type: EXPERIMENTAL
Intervention: Crank arm length of 175 mm
Number of subjects: 6
Study 9356762 — intervention group
Group type: EXPERIMENTAL
Intervention: High, medium, or low efficiency categories based on VO2.m‐1.min‐1 values
Number of subjects: 6
Study 9356762 — intervention group
Group type: COMPARATOR
Intervention: Leg length correlation
Number of subjects: 6
Study 8228792 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IMA) with combined anticoagulation using heparin and citrate
Number of subjects: 9
Study 8228792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran sulfate adsorption (DSA) with heparin exclusively
Number of subjects: 9
Study 28987615 — intervention group
Group type: EXPERIMENTAL
Intervention: MS Care collaborative care intervention
Number of subjects: 0
Study 28987615 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 28499657 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically Assisted Movement Therapy (EAMT)
Number of subjects: 11
Study 28499657 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (dose-matched, goal-oriented)
Number of subjects: 11
Study 28499657 — intervention group
Group type: EXPERIMENTAL
Intervention: EAMT
Number of subjects: 11
Study 26011775 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 10
Study 26011775 — intervention group
Group type: COMPARATOR
Intervention: EVOLVE RCT
Number of subjects: 10
Study 23122489 — intervention group
Group type: EXPERIMENTAL
Intervention: Contracting, prompting and reinforcing (CPR)
Number of subjects: 92
Study 23122489 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (STX)
Number of subjects: 92
Study 21970918 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Hip Replacement (THR)
Number of subjects: 60
Study 21970918 — intervention group
Group type: COMPARATOR
Intervention: HemiArthroplasty (HA)
Number of subjects: 60
Study 18667747 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence-guided resections using 5-aminolevulinic acid (ALA)
Number of subjects: 243
Study 18667747 — intervention group
Group type: COMPARATOR
Intervention: Control group (without ALA)
Number of subjects: 243
Study 16449099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg/d for the first week, 20 mg/d for the second week)
Number of subjects: 60
Study 16449099 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (25 mg/d for the first week, 50 mg/d for the second week)
Number of subjects: 60
Study 12778623 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine porous bone mineral (BPBM) with guided tissue regeneration (GTR)
Number of subjects: 26
Study 12778623 — intervention group
Group type: COMPARATOR
Intervention: Bovine porous bone mineral (BPBM) with autologous fibrinogen/fibronectin system (AFFS)
Number of subjects: 26
Study 10659481 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine group
Number of subjects: 83
Study 10659481 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 83
Study 9341573 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment arm
Number of subjects: 242
Study 9341573 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment arm
Number of subjects: 242
Study 9341573 — intervention group
Group type: EXPERIMENTAL
Intervention: TIA (within 6 months)
Number of subjects: 242
Study 9341573 — intervention group
Group type: EXPERIMENTAL
Intervention: TIA (after year 3)
Number of subjects: 242
Study 9341573 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall reporting for TIA
Number of subjects: 242
Study 9341573 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall reporting for stroke
Number of subjects: 242
Study 8416020 — intervention group
Group type: EXPERIMENTAL
Intervention: Tridimensional Personality Questionnaire (TPQ) scores
Number of subjects: 27
Study 8416020 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise regression model of severity of purging on TPQ
Number of subjects: 27
Study 8416020 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood serotonin levels
Number of subjects: 27
Study 8416020 — intervention group
Group type: COMPARATOR
Intervention: TPQ scores of bulimic women
Number of subjects: 27
Study 3699011 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining with cycling one day per week at 40 degrees C
Number of subjects: 16
Study 3699011 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining with cycling one day per week at 20 degrees C
Number of subjects: 16
Study 3699011 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining with resting one day per week at 40 degrees C
Number of subjects: 16
Study 3699011 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 16
Study 30938624 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric embolization
Number of subjects: 20
Study 30015709 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about the frequency and undertreatment of pain in the older adult (undertreatment)
Number of subjects: 165
Study 30015709 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about the possibility of secondary gain (misuse)
Number of subjects: 165
Study 30015709 — intervention group
Group type: COMPARATOR
Intervention: Neutral information (control)
Number of subjects: 165
Study 26450639 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100mg
Number of subjects: 4330
Study 26450639 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300mg
Number of subjects: 4330
Study 26450639 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4330
Study 26450639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4330
Study 25096608 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (specific regimen not detailed)
Number of subjects: 29011
Study 22362035 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-fixating composite mesh
Number of subjects: 394
Study 22362035 — intervention group
Group type: COMPARATOR
Intervention: Sutured lightweight mesh
Number of subjects: 394
Study 20452703 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support in computerized physician order entry system
Number of subjects: 2783
Study 20452703 — intervention group
Group type: COMPARATOR
Intervention: Control group (no decision support)
Number of subjects: 2783
Study 18030084 — intervention group
Group type: EXPERIMENTAL
Intervention: SET-C
Number of subjects: 0
Study 18030084 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 18030084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15983962 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone, 50 mg, orally twice daily for 2 weeks
Number of subjects: 8
Study 15983962 — intervention group
Group type: COMPARATOR
Intervention: Placebo, orally twice daily for 2 weeks
Number of subjects: 8
Study 12853744 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART + IL-2
Number of subjects: 0
Study 12853744 — intervention group
Group type: COMPARATOR
Intervention: HAART
Number of subjects: 0
Study 10539816 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 3918
Study 10539816 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 3918
Study 10539816 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure
Number of subjects: 3918
Study 10539816 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index and height
Number of subjects: 3918
Study 10539816 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular mass and wall thickness/chamber radius ratio
Number of subjects: 3918
Study 8732962 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg
Number of subjects: 22
Study 8732962 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.05 mg
Number of subjects: 22
Study 8732962 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.125 mg
Number of subjects: 22
Study 8732962 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.25 mg
Number of subjects: 22
Study 8732962 — intervention group
Group type: COMPARATOR
Intervention: Baseline cortisol values
Number of subjects: 22
Study 1815967 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg emiglitate
Number of subjects: 0
Study 1815967 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg emiglitate
Number of subjects: 0
Study 1815967 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg emiglitate
Number of subjects: 0
Study 1815967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6808657 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin 0.4 g
Number of subjects: 12
Study 6808657 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin 1 g
Number of subjects: 12
Study 6808657 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin 2 g
Number of subjects: 12